Tearsheet
Investment Highlights Market Valuation Price Chart Business Description Interactive Breakdown Latest Trefis Analyses Better Bets vs. JNJ Recent Active Movers More From Trefis Peer Financials Peer Growth & Margins Peer Valuation Peer Returns Peer Analyses FDIC Bank Data Financials Segment Financials Price Behavior Short Interest Earnings Returns History SEC Filings Insider Activity Industry Resource Links External Quote Links

Johnson & Johnson (JNJ)

Market Price (9/18/2025): $177.1 | Market Cap: $426.2 Bil
Sector: Health Care | Industry: Pharmaceuticals

Johnson & Johnson (JNJ)

Market Price (9/18/2025): $177.1
Market Cap: $426.2 Bil
Sector: Health Care
Industry: Pharmaceuticals

Investment Highlights

0 Attractive yield
Total YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 8.1%, Dividend Yield is 2.8%, ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is 3.7%		 Trading close to highs
Dist 52W High is -0.9%, Dist 3Y High is -0.9%		 
1 Attractive operating margins
Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is 25%		 Weak multi-year price returns
2Y Excs Rtn is -33%, 3Y Excs Rtn is -43%		 
2 Attractive cash flow generation
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 25%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 18%, CFO LTM is 23 Bil, FCF LTM is 16 Bil		  
3 Low stock price volatility
Vol 12M is 19%		  
0 Attractive yield
Total YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 8.1%, Dividend Yield is 2.8%, ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is 3.7%
1 Attractive operating margins
Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is 25%
2 Attractive cash flow generation
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 25%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 18%, CFO LTM is 23 Bil, FCF LTM is 16 Bil
3 Low stock price volatility
Vol 12M is 19%
4 Trading close to highs
Dist 52W High is -0.9%, Dist 3Y High is -0.9%
5 Weak multi-year price returns
2Y Excs Rtn is -33%, 3Y Excs Rtn is -43%

Market Valuation

 9/18/252024202320222021
Share Price CYE$177.10$141.22$148.35$162.27$153.12
Market Cap CYE ($ Bil)426.2339.9357.1426.4403.1
Total Debt ($ Bil)50.836.629.339.633.8
Total Cash ($ Bil)18.924.522.922.331.6
Enterprise Value ($ Bil)458.0376.5386.4466.0436.9
Valuation Ratios     
P/S TTM4.73.94.75.85.7
P/EBIT TTM15.120.025.123.623.3
P/E TTM18.824.811.325.921.6
Sector Ratios     
P/S TTM (Sector)3.83.64.14.57.3
P/EBIT TTM (Sector)-1.6-1.3-1.4-1.3-2.9
P/E TTM (Sector)-1.8-1.5-1.5-1.3-2.9
 9/18/2520242023
Share Price CYE$177.10$141.22$148.35
Market Cap CYE ($ Bil)426.2339.9357.1
Total Debt ($ Bil)50.836.629.3
Total Cash ($ Bil)18.924.522.9
Enterprise Value ($ Bil)458.0376.5386.4
Valuation Ratios   
P/S TTM4.73.94.7
P/EBIT TTM15.120.025.1
P/E TTM18.824.811.3
Sector Ratios   
P/S TTM (Sector)3.83.64.1
P/EBIT TTM (Sector)-1.6-1.3-1.4
P/E TTM (Sector)-1.8-1.5-1.5

Market Cap Chart

Business Description

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products. Show more

Price Returns Compared

Expand for Detailed View

 202020212022202320242025Total [1]
Returns
JNJ Return11%11%6%-9%-5%25%44%
Peers Return10%34%23%-1%12%-2%97%
S&P 500 Return16%27%-19%24%23%12%104%

[1] Cumulative total returns since the beginning of 2020
[2] Peers: LLY, ABBV, MRK, PFE, BMY. See JNJ Returns vs. Peers.
[3] 2025 data is for the year up to 9/17/2025 (YTD)

Interactive Breakdown

Johnson & Johnson Interactive Breakdown Analysis

Better Bets than Johnson & Johnson (JNJ)

 JNJBetter Performance than JNJ
MetricValueIndustry (Pharmaceuticals)
Rev Chg LTM4.7%LLY (36.8%), PFE (13.5%), ZTS (5.3%), CORT (25.7%), ACAD (14.4%)
Rev Chg 3Y Avg4.0%LLY (23.4%), ZTS (5.5%), JAZZ (5.5%), CORT (22.7%), ALKS (9.2%)
Op Mgn LTM24.5%LLY (43.0%), MRK (31.2%), PFE (26.1%), ZTS (37.5%), ALKS (24.9%)
CFO/Rev LTM25.4%MRK (29.1%), BMY (30.0%), ZTS (31.2%), JAZZ (32.2%), CORT (25.4%)
FCF/Rev LTM18.1%MRK (23.1%), PFE (19.5%), BMY (27.5%), ZTS (23.6%), JAZZ (30.3%)
Total Yield8.1%MRK (12.0%), PFE (13.2%), BMY (11.0%), OGN (34.2%), AMPH (10.6%)
 JNJBetter Performance than JNJ
MetricValueAll Other Sectors
Rev Chg LTM4.7%NVDA (71.6%), MSFT (14.9%), AAPL (6.0%), GOOGL (13.1%), AMZN (10.9%)
Rev Chg 3Y Avg4.0%NVDA (92.0%), MSFT (12.5%), GOOGL (10.2%), AMZN (11.3%), META (13.0%)
Op Mgn LTM24.5%NVDA (58.1%), MSFT (45.6%), AAPL (31.9%), GOOGL (32.7%), META (42.9%)
CFO/Rev LTM25.4%NVDA (46.6%), MSFT (48.3%), AAPL (26.6%), GOOGL (36.0%), META (56.4%)
FCF/Rev LTM18.1%NVDA (43.6%), MSFT (25.4%), AAPL (23.5%), META (30.7%), AVGO (41.6%)
Total Yield8.1%XOM (9.7%), BABA (37.9%), CVX (9.2%), WFC (9.7%), TM (2077.1%)

Latest Trefis Analyses

TitleTopicDate
0DASHBOARDS  
1Johnson & Johnson Earnings Notes  
2A Decade of Rewards: JNJ Returns $157 Bil to Investors  
3Johnson & Johnson vs United Therapeutics: Which Is A Better Investment?Counter-Intuitive Comparisons 
4How Does JNJ Stack Up Against Its Peers?Peer Comparison 
5Better Bet Than JNJ Stock: Pay Less Than Johnson & Johnson To Get More From PM, UNH   
6Better Bet Than JNJ Stock: Pay Less Than Johnson & Johnson To Get More From UNH, HCA   
7Better Bet Than JNJ Stock: Pay Less Than Johnson & Johnson To Get More From AMRX, JAZZ, NVS, PAHC Actionable 
8[7/15/2025] Better Bet Than JNJ Stock: Pay Less Than Johnson & Johnson To Get More From Sector Peers EHC, CNMD, HCA, AVAH Better Bets 
9[7/15/2025] Better Bet Than JNJ Stock: Pay Less Than Johnson & Johnson To Get More From Industry Peers NVS, MRK, AMRX, BHC Better Bets 
10[7/15/2025] Better Bet Than JNJ Stock: Pay Less Than Johnson & Johnson To Get More From S&P 500 Stocks NVS, MRK, AMRX, BHC Better Bets 
11ARTICLES  
12Is Rerating Around The Corner For Johnson & Johnson Stock? September 9th, 2025
13JNJ Has Paid Out $157 Bil to Investors in the Past Decade August 21st, 2025
14S&P 500 Stocks Trading At 52-Week High August 21st, 2025
15S&P 500 Stocks Trading At 52-Week High August 20th, 2025
16S&P 500 Stocks Trading At 52-Week High August 16th, 2025
Title
0DASHBOARDS
1Is Rerating Around The Corner For Johnson & Johnson Stock?
2JNJ Has Paid Out $157 Bil to Investors in the Past Decade
3S&P 500 Stocks Trading At 52-Week High
4S&P 500 Stocks Trading At 52-Week High
5S&P 500 Stocks Trading At 52-Week High
6ARTICLES
7Johnson & Johnson Earnings Notes
8A Decade of Rewards: JNJ Returns $157 Bil to Investors
9Johnson & Johnson vs United Therapeutics: Which Is A Better Investment?
10How Does JNJ Stack Up Against Its Peers?
11Better Bet Than JNJ Stock: Pay Less Than Johnson & Johnson To Get More From PM, UNH 
12Better Bet Than JNJ Stock: Pay Less Than Johnson & Johnson To Get More From UNH, HCA 
13Better Bet Than JNJ Stock: Pay Less Than Johnson & Johnson To Get More From AMRX, JAZZ, NVS, PAHC 
14[7/15/2025] Better Bet Than JNJ Stock: Pay Less Than Johnson & Johnson To Get More From Sector Peers EHC, CNMD, HCA, AVAH 
15[7/15/2025] Better Bet Than JNJ Stock: Pay Less Than Johnson & Johnson To Get More From Industry Peers NVS, MRK, AMRX, BHC 
16[7/15/2025] Better Bet Than JNJ Stock: Pay Less Than Johnson & Johnson To Get More From S&P 500 Stocks NVS, MRK, AMRX, BHC 

Recent Active Movers

1 Week Top Gainers

#TickerCompany1W RtnYTD Rtn
1ECDAECD Automotive Design3347.2%307.9%
2BDSXBiodesix1090.6%-79.7%
3CLSDClearside Biomedical987.7%-74.7%
4ATHAAthira Pharma892.1%544.3%
5SDOTSadot690.6%-79.9%
6ATCHAtlasClear684.9%-83.1%
7HSDTHelius Medical Technologies232.1%-95.5%
8CHEKCheck-Cap222.2%134.4%
9APLMApollomics197.8%89.1%
10SPRCSciSparc147.0%1141.7%

1 Week Top Losers

#TickerCompany1W RtnYTD Rtn
1CURXCuranex Pharmaceuticals-80.5%148.4%
2ATYRaTyr Pharma-80.4%-71.7%
3NAKAKindly MD-70.2% 
4BNGOBionano Genomics-64.0%-89.8%
5XAGELongevity Health-57.6%-86.1%
6FAASDigiAsia-55.4%-88.0%
7ASSTStrive-54.5%650.3%
8VCIGVCI Global-51.0%-98.9%
9REXREX American Resources-50.7%44.3%
10RBNERobin Energy-42.6% 

1 Month Top Gainers

#TickerCompany1M RtnYTD Rtn
1PMIPicard Medical11931.7%11931.7%
2GIBOGIBO10714.0% 
3LNZALanzaTech Global8455.2%-86.3%
4GTIGraphjet Technology3998.4%-93.1%
5GWAVGreenwave Technology Solutions3582.8%-91.4%
6QMMMQMMM3409.6%8153.1%
7ECDAECD Automotive Design2715.2%307.9%
8OESXOrion Energy Systems1373.7%14.2%
9OPOceanPal1266.5%-95.6%
10BCTXBriaCell Therapeutics1032.4%-89.8%

1 Month Top Losers

#TickerCompany1M RtnYTD Rtn
1CJETChijet Motor-94.5%-96.0%
2STFSStar Fashion Culture-92.3%-97.9%
3ELPWElong Power-91.1%-76.9%
4NXTTNext Technology-90.1%-95.4%
5EPIXESSA Pharma-89.4%-8.9%
6NAKAKindly MD-88.1% 
7BINIBollinger Innovations-87.6%-100.0%
8JEM707 Cayman-87.4%-98.2%
9YAASYouxin Technology-83.3%-98.4%
10NEONNeonode-82.5%-51.0%

Recent Active Movers

1 Week Top Gainers

#TickerCompany1W RtnYTD Rtn
1ECDAECD Automotive Design3347.2%307.9%
2BDSXBiodesix1090.6%-79.7%
3CLSDClearside Biomedical987.7%-74.7%
4ATHAAthira Pharma892.1%544.3%
5SDOTSadot690.6%-79.9%
6ATCHAtlasClear684.9%-83.1%
7HSDTHelius Medical Technologies232.1%-95.5%
8CHEKCheck-Cap222.2%134.4%
9APLMApollomics197.8%89.1%
10SPRCSciSparc147.0%1141.7%

1 Week Top Losers

#TickerCompany1W RtnYTD Rtn
1CURXCuranex Pharmaceuticals-80.5%148.4%
2ATYRaTyr Pharma-80.4%-71.7%
3NAKAKindly MD-70.2% 
4BNGOBionano Genomics-64.0%-89.8%
5XAGELongevity Health-57.6%-86.1%
6FAASDigiAsia-55.4%-88.0%
7ASSTStrive-54.5%650.3%
8VCIGVCI Global-51.0%-98.9%
9REXREX American Resources-50.7%44.3%
10RBNERobin Energy-42.6% 

More From Trefis

Research & Analysis

Invest in Strategies

Wealth Management

Peer Comparisons for Johnson & Johnson

Financials

JNJLLYABBVMRKPFEBMYMedian
NameJohnson .Eli LillyAbbVie Merck Pfizer Bristol-. 
Mkt Price177.20760.13220.8181.1424.0546.15129.17
Mkt Cap426.4682.5390.4203.7136.793.7297.0
Rev LTM90,62753,25858,32863,61663,83347,63660,972
Op Inc LTM22,22822,88213,69519,82116,6637,87018,242
FCF LTM16,397-5018,23914,72212,43813,08613,904
FCF 3Y Avg16,926-15620,27312,8999,30412,22512,562
CFO LTM23,02810,93819,28318,53415,18814,31016,861
CFO 3Y Avg22,2487,23021,15416,76612,58413,41915,093

Growth & Margins

JNJLLYABBVMRKPFEBMYMedian
NameJohnson .Eli LillyAbbVie Merck Pfizer Bristol-. 
Rev Chg LTM4.7%36.8%6.1%1.8%13.5%4.6%5.4%
Rev Chg 3Y Avg4.0%23.4%0.6%3.7%-12.4%0.5%2.1%
Rev Chg Q5.8%37.6%6.6%-1.9%10.3%-5.6%6.2%
QoQ Delta Rev Chg LTM1.5%8.7%1.7%-0.5%2.2%-1.4%1.6%
Op Mgn LTM24.5%43.0%23.5%31.2%26.1%16.5%25.3%
Op Mgn 3Y Avg26.3%35.6%27.2%22.6%20.2%17.3%24.4%
QoQ Delta Op Mgn LTM-0.2%1.8%1.0%-0.8%1.8%4.3%1.4%
CFO/Rev LTM25.4%20.5%33.1%29.1%23.8%30.0%27.3%
CFO/Rev 3Y Avg25.7%17.8%37.5%27.2%18.8%28.9%26.5%
FCF/Rev LTM18.1%-0.1%31.3%23.1%19.5%27.5%21.3%
FCF/Rev 3Y Avg19.6%0.5%36.0%20.9%13.8%26.4%20.2%

Valuation

JNJLLYABBVMRKPFEBMYMedian
NameJohnson .Eli LillyAbbVie Merck Pfizer Bristol-. 
Mkt Cap426.4682.5390.4203.7136.793.7297.0
P/S4.712.86.73.22.12.04.0
P/EBIT15.138.466.310.010.211.513.3
P/E18.849.5103.712.412.717.318.1
P/CFO18.562.420.211.09.06.614.8
Total Yield8.1%2.8%3.9%12.0%13.2%11.0%9.6%
Dividend Yield2.8%0.7%2.9%3.9%5.3%5.2%3.4%
FCF Yield 3Y Avg4.5%0.1%7.3%5.1%5.7%12.4%5.4%
D/E0.10.10.20.20.40.50.2
Net D/E0.10.10.20.10.30.40.1

Returns

JNJLLYABBVMRKPFEBMYMedian
NameJohnson .Eli LillyAbbVie Merck Pfizer Bristol-. 
1M Rtn1.3%8.9%6.9%-2.7%-4.1%-4.2%-0.7%
3M Rtn18.4%-3.0%20.1%3.3%2.4%-1.5%2.9%
6M Rtn10.5%-8.8%5.9%-12.0%-4.9%-22.4%-6.8%
12M Rtn9.5%-15.5%18.2%-28.9%-13.7%-3.6%-8.7%
3Y Rtn15.8%152.3%71.6%1.2%-38.4%-27.7%8.5%
1M Excs Rtn-1.1%6.5%4.5%-5.0%-6.4%-6.6%-3.1%
3M Excs Rtn6.8%-14.0%9.8%-5.6%-8.4%-12.6%-7.0%
6M Excs Rtn-7.9%-24.7%-12.4%-30.2%-22.8%-39.7%-23.8%
12M Excs Rtn-6.8%-34.4%0.4%-44.2%-29.4%-20.2%-24.8%
3Y Excs Rtn-43.4%86.7%13.2%-59.1%-101.2%-89.1%-51.2%

Comparison Analyses

Financials

$ Mil | FY: 12/292025Q22025Q12024Q42024Q32024Q22024Q12023Q42023Q32023Q22023Q12022Q42022Q3
Period End6/29/20253/30/202512/29/20249/29/20246/30/20243/31/202412/31/202310/1/20237/2/20234/2/20231/1/202310/2/2022
Filing Date7/24/20254/23/20252/13/202510/23/20247/25/20245/1/20242/16/202410/27/20237/31/20234/28/20232/16/202310/27/2022
Key Financials Quarterly            
Total Revenue23,74321,89322,52022,47122,44721,38321,39521,35121,51920,89419,93919,996
Ebitda8,74215,6075,9205,3777,8005,6846,8207,2388,4578055,7896,908
Operating Income6,8106,2993,8415,2786,6576,2734,6076,1986,3586,2463,9065,664
Net Income5,53710,9993,4312,6944,6863,2554,04926,0285,144-683,5204,458
EPS2.304.571.431.121.951.351.6810.321.98-0.031.351.70
Key Financials TTM            
Total Revenue TTM90,62789,33188,82187,69686,57685,64885,15983,70382,34884,84987,38177,211
Ebitda TTM35,64634,70424,78125,68127,54228,19923,32022,28921,95921,12427,96025,312
Operating Income TTM22,22822,07522,04922,81523,73523,43623,40922,70822,17422,28822,16019,125
Net Income TTM22,66121,81014,06614,68438,01838,47635,15334,62413,05412,72417,94119,157
Growth Rates Quarterly            
Total Revenue Growth5.8%2.4%5.3%5.2%4.3%2.3%7.3%6.8%-10.4%-10.8%104.1%-14.3%
EBITDA Growth12.1%174.6%-13.2%-25.7%-7.8%606.1%17.8%4.8%11.0%-89.5%84.3%21.6%
Operating Income Growth2.3%0.4%-16.6%-14.8%4.7%0.4%17.9%9.4%-1.8%2.1%348.5%-17.5%
Net Income Growth18.2%237.9%-15.3%-89.6%-8.9%4886.8%15.0%483.8%6.9%-101.3%-25.7%21.6%
Margins Quarterly            
EBITDA Margin36.8%71.3%26.3%23.9%34.7%26.6%31.9%33.9%39.3%3.9%29.0%34.5%
Operating Income Margin28.7%28.8%17.1%23.5%29.7%29.3%21.5%29.0%29.5%29.9%19.6%28.3%
Net Income Margin23.3%50.2%15.2%12.0%20.9%15.2%18.9%121.9%23.9%-0.3%17.7%22.3%
Cash & Debt            
Total Cash18,88038,78124,52220,29725,47526,21822,92723,51128,50524,61322,28134,079
Total Debt50,76152,25236,63435,75141,49133,63229,33229,92145,60252,90739,64232,027
Net Debt / (Cash)31,88113,47112,11215,45416,0167,4146,4056,41017,09728,29417,361-2,052
Cash Flows Quarterly            
FCF from Operations3,8784,1746,9837,9935,6333,6577,8637,4894,1823,2575,3506,284
Cash Flows TTM            
FCF from Operations TTM23,02824,78324,26625,14624,64223,19122,79120,27819,07320,47221,19421,576
Returns to Shareholders Quarterly            
Dividends3,1292,9892,9842,9852,9852,8692,8652,8713,0922,9422,9542,970
Share Repurchases-02,1272825391361,4752169203813,5371,3202,165
Return on Invested Capital (ROIC) Quarterly            
ROIC67.1%129.7%112.0%110.3%135.5%296.6%246.3%319.5%45.1%17.3%25.0%60.1%
Return on Invested Capital (ROIC) TTM            
ROIC TTM53.2%115.5%153.4%123.7%124.5%269.0%323.4%312.6%40.9%35.4%35.7%53.6%

Segment Financials

Revenue by Segment

$ Mil20242023202220212020
Innovative Medicine54,75952,56351,68045,57242,198
MedTech30,40027,42727,06022,95925,963
Consumer Health   14,05313,898
Total85,15979,99078,74082,58482,059


Assets by Segment
$ Mil20242023202220212020
MedTech74,710  49,57849,462
Innovative Medicine58,324  66,15856,292
General corporate34,524  31,80325,356
Consumer Health   27,35526,618
Total167,558  174,894157,728


Price Behavior

JNJ Betas & Captures as of 8/31/2025

 1M2M3M6M1Y3Y
Beta-0.080.110.210.100.060.17
Up Beta0.650.040.020.050.080.20
Down Beta-0.82-0.92-0.390.120.030.20
Up Capture41%101%72%16%6%3%
Bmk +ve Days10223571142415
Stock +ve Days14253872135396
Down Capture-108%-34%3%10%0%26%
Bmk -ve Days11192754106334
Stock -ve Days7172554114353

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively

Short Interest

Short Interest: As Of Date8292025
Short Interest: Shares Quantity18,836,072
Short Interest: % Change Since 81520251.7%
Average Daily Volume8,066,488
Days-to-Cover Short Interest2.34
Basic Shares Quantity2,406,300,000
Short % of Basic Shares0.8%

Returns Analyses

Earnings Returns History

Expand for More

 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
7/16/20256.2%8.2%12.4%
4/15/2025-0.5%2.2%-5.2%
1/22/2025-1.9%1.5%8.6%
10/15/20241.5%0.8%-5.5%
7/17/20243.7%0.9%4.9%
4/16/2024-2.1%1.0%2.6%
1/23/2024-1.6%-1.9%-1.6%
10/17/2023-0.9%-3.9%-6.3%
...
SUMMARY STATS   
# Positive141612
# Negative10812
Median Positive2.5%2.3%4.9%
Median Negative-1.5%-2.0%-3.1%
Max Positive6.2%8.8%12.4%
Max Negative-2.8%-5.0%-6.3%

SEC Filings

Expand for More

Report DateFiling DateFiling
6302025724202510-Q 6/29/2025
3312025423202510-Q 3/30/2025
12312024213202510-K 12/29/2024
93020241023202410-Q 9/29/2024
6302024725202410-Q 6/30/2024
3312024501202410-Q 3/31/2024
12312023216202410-K 12/31/2023
93020231027202310-Q 10/1/2023
6302023731202310-Q 7/2/2023
3312023428202310-Q 4/2/2023
12312022216202310-K 1/1/2023
93020221027202210-Q 10/2/2022
6302022729202210-Q 7/3/2022
3312022429202210-Q 4/3/2022
12312021217202210-K 1/2/2022
93020211029202110-Q 10/3/2021

Insider Activity

Expand for More

 OwnerTitleFiling DateActionPriceSharesTransacted
Value		Value of
Held Shares		Form
0REED JOHN CEVP, Innovative Medicine, R&D7182025Sell163.5519,1373,129,8301,743,101Form
1WEINBERGER MARK A 12122024Buy147.221,000147,220147,220Form

Industry Resources

External Quote Links


Prefer one of these to Trefis? Tell us why.